Both are FDA-approved for chronic weight management, but they contain different active ingredients. Zepbound contains tirzepatide, which activates both GLP-1 and GIP receptors (dual agonist), while Wegovy contains semaglutide, which activates GLP-1 receptors only. In clinical trials, tirzepatide produced greater average weight loss than semaglutide, though individual responses vary. Your provider can help determine which is right for you.